Immunovant (NASDAQ:IMVT) Share Price Crosses Below Two Hundred Day Moving Average - Here's What Happened

Immunovant logo with Healthcare background
Image from MarketBeat Media, LLC.

Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $32.50 and traded as low as $31.61. Immunovant shares last traded at $31.77, with a volume of 704,202 shares traded.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IMVT. Wall Street Zen upgraded Immunovant from a "sell" rating to a "hold" rating in a research note on Saturday, November 14th. UBS Group restated a "buy" rating on shares of Immunovant in a research note on Wednesday, September 23rd. HC Wainwright reaffirmed a "buy" rating on shares of Immunovant in a research report on Thursday, September 24th. JPMorgan Chase & Co. boosted their target price on Immunovant from $47.00 to $50.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Finally, Citigroup reaffirmed a "positive" rating on shares of Immunovant in a report on Thursday, September 24th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $44.60.

Read Our Latest Research Report on Immunovant

Immunovant Stock Down 2.3%

The firm has a market capitalization of $6.57 billion, a PE ratio of -12.41 and a beta of 0.95. The stock's fifty day simple moving average is $32.06 and its 200 day simple moving average is $32.50.

Immunovant (NASDAQ:IMVT - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.27. During the same period in the prior year, the firm earned ($0.73) earnings per share. On average, analysts predict that Immunovant, Inc. will post -2.49 EPS for the current year.

Insider Transactions at Immunovant

In other Immunovant news, COO Melanie Gloria sold 2,241 shares of the firm's stock in a transaction dated Wednesday, October 7th. The stock was sold at an average price of $32.06, for a total transaction of $71,846.46. Following the sale, the chief operating officer directly owned 217,060 shares of the company's stock, valued at $6,958,943.60. This trade represents a 1.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CTO Jay S. Stout sold 2,595 shares of the business's stock in a transaction dated Wednesday, October 21st. The shares were sold at an average price of $28.94, for a total value of $75,099.30. Following the completion of the transaction, the chief technology officer owned 198,937 shares in the company, valued at $5,757,236.78. The trade was a 1.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 27,430 shares of company stock valued at $895,852. Company insiders own 1.90% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in Immunovant during the second quarter valued at approximately $276,680,000. Two Seas Capital LP grew its holdings in Immunovant by 46.5% during the 3rd quarter. Two Seas Capital LP now owns 4,612,692 shares of the company's stock valued at $155,817,000 after buying an additional 1,464,187 shares in the last quarter. ADAR1 Capital Management LLC increased its stake in Immunovant by 8.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,679,010 shares of the company's stock worth $66,547,000 after acquiring an additional 198,042 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Immunovant during the 2nd quarter valued at approximately $45,521,000. Finally, Aberdeen Group plc increased its position in Immunovant by 2.6% in the third quarter. Aberdeen Group plc now owns 879,334 shares of the company's stock worth $29,704,000 after purchasing an additional 22,304 shares during the last quarter. 47.08% of the stock is owned by hedge funds and other institutional investors.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company's investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves' disease and other autoimmune disorders.

Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Immunovant Right Now?

Before you consider Immunovant, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunovant wasn't on the list.

While Immunovant currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines